Louise Schmidt
Biographic Data
| ID | 9570353 |
|---|---|
| NAME | Louise Schmidt |
| GIVEN NAMES | Louise |
| FAMILY NAME | Schmidt |
| SIGNATURE | SCHMIDT L |
| AFFILIATIONS | Austrian Institute for Health Technology Assessment GmbH |
| ORCID | 0000-0001-6062-7065 |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2002 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Public contributions to R&D of medical innovations
Article 57 of the Directive of the (proposed) Pharmaceutical Legislation (PL) will require market authorization applicants) to publicly declare any direct financial support for R&D activities received from public authorities. • Public contributions to R&D of products are manifold, but not well documented. • Aligned public policies enforcing transparency on R&D investments are key for the implementation of the transparency clause. • Standardizatio…
Quality of life measurement
Objectives: To assess the growth of quality of life measures and to examine the availability of measures across specialties. Design: Systematic searches of electronic databases to identify developmental and evaluative work relating to health outcome measures assessed by patients. Main outcome measures: Types of measures: disease or population specific, dimension specific, generic, individualised, and utility. Specialties in which measures have be…
No prominent works on this page.
Quality of life measurement
Objectives: To assess the growth of quality of life measures and to examine the availability of measures across specialties. Design: Systematic searches of electronic databases to identify developmental and evaluative work relating to health outcome measures assessed by patients. Main outcome measures: Types of measures: disease or population specific, dimension specific, generic, individualised, and utility. Specialties in which measures have be…
Public contributions to R&D of medical innovations
Article 57 of the Directive of the (proposed) Pharmaceutical Legislation (PL) will require market authorization applicants) to publicly declare any direct financial support for R&D activities received from public authorities. • Public contributions to R&D of products are manifold, but not well documented. • Aligned public policies enforcing transparency on R&D investments are key for the implementation of the transparency clause. • Standardizatio…
Health Systems, Economic Evaluations, Quality of Life (2 works) · Medicine (2 works) · Alternative medicine (1 work) · Biomedical Ethics and Regulation (1 work) · Business (1 work) · Cancer survivorship and care (1 work) · Disease (1 work) · Economics (1 work) · Environmental health (1 work) · Family medicine (1 work)